develop
vaccin
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
crucial
prevent
sar
reemerg
receptorbind
domain
rbd
sarscov
spike
protein
import
target
develop
safe
effect
sar
vaccin
previou
studi
demonstr
vaccin
adenoassoci
viru
encod
rbd
rbdraav
induc
high
titer
neutral
antibodi
studi
assess
immun
respons
protect
effect
immun
rbdraav
primerbdspecif
cell
peptid
boost
compar
rbdraav
primeboost
vaccin
rbdraav
primerbdpeptid
rbdpep
boost
induc
similar
level
neutral
antibodi
respons
protect
vaccin
mice
subsequ
sarscov
challeng
stronger
ctl
respons
signific
immun
respons
protect
effect
detect
mice
vaccin
rbdpep
blank
aav
alon
sinc
cell
epitop
highli
conserv
boost
peptid
may
induc
product
effector
memori
cell
may
effect
virus
mutat
neutral
epitop
result
suggest
vaccin
protocol
use
may
ideal
provid
effect
broad
longterm
protect
sarscov
infect
sever
acut
respiratori
syndrom
sar
latestreport
emerg
infecti
diseas
caus
sar
coronaviru
sarscov
sinc
end
sar
outbreak
juli
number
sar
case
sporad
report
rais
seriou
safeti
concern
presenc
natur
reservoir
also
suggest
risk
reintroduct
sarscovlik
viru
anim
human
develop
prevent
strategi
particularli
gener
effect
safe
vaccin
sarscov
therefor
import
task
current
sar
research
exist
vaccin
candid
sarscov
base
protein
studi
shown
vaccin
african
green
monkey
attenu
parainfluenza
viru
encod
sarscov
protein
result
product
sarscovspecif
neutral
antibodi
protect
vaccin
anim
subsequ
sarscov
challeng
also
indic
among
structur
protein
sarscov
signific
neutral
protect
antigen
singl
mucos
immun
protein
effici
suppress
sarscov
infect
furthermor
receptorbind
domain
rbd
fragment
protein
demonstr
major
neutral
determin
develop
subunit
vaccin
sar
report
suggest
protein
sarscov
especi
rbd
highli
effect
prevent
sar
recent
report
strategi
use
combin
differ
vaccin
improv
humor
cellular
immun
respons
prime
sarscov
sexpress
dna
boost
adenovir
vector
encod
induc
optim
cell
immun
boost
inactiv
sarscov
plu
adjuv
stimul
cell
immun
antibodi
respons
humor
immun
respons
secret
also
enhanc
prime
dnabas
vaccin
boost
recombin
adenoviru
encod
n
protein
sarscov
report
demonstr
ideal
sar
vaccin
develop
ration
design
appropri
primeboost
strategi
previous
report
recombin
adenoassoci
viru
encod
rbd
sarscov
protein
rbdraav
induc
sarscovspecif
igg
antibodi
neutral
activ
rbd
region
cell
epitop
residu
nynykyrylr
cell
epitop
residu
kcygvsatkl
identifi
respect
studi
prime
rbdraav
boost
rbdpeptid
rbdpep
specif
cell
epitop
compar
immun
respons
protect
effect
vaccin
rbdraav
rbdpep
alon
mous
model
rbdraav
produc
previous
describ
briefli
rbdraav
plasmid
cotransfect
phelper
paavrc
plasmid
cell
use
calcium
phosphat
transfect
method
stratagen
usa
accord
manufactur
protocol
transfect
cell
supernat
harvest
h
posttransfect
purif
titrat
describ
previous
rbdraav
adjust
viral
particl
vp
ml
pb
peptid
cell
epitop
cell
epitop
deriv
rbd
sarscov
protein
plu
cpg
oligodeoxynucleotid
odn
tcc
atg
acg
ttc
ctg
acg
tt
rbdpep
use
prime
boost
immun
studi
femal
balbc
mice
age
week
use
vaccin
mice
studi
purchas
laboratori
anim
unit
lau
univers
hong
kong
anim
hous
anim
facil
depart
microbiolog
univers
hong
kong
maintain
accord
anim
care
protocol
anim
studi
approv
depart
health
govern
hong
kong
special
administr
region
sar
mice
vaccin
follow
protocol
describ
previous
mice
separ
four
group
nine
mice
per
group
prime
rbdraav
intramuscular
im
l
rbdpep
g
plu
cpg
odn
g
subcutan
sc
blank
aav
boost
rbdraav
rbdpep
aav
respect
group
divid
two
subgroup
five
mice
subgroup
four
mice
subgroup
forti
day
first
immun
mice
subgroup
anaesthet
diethyl
ether
sera
collect
retroorbit
punctur
detect
igg
na
elisa
neutral
assay
respect
spleen
harvest
detect
cell
immun
elispot
flow
cytometri
analysi
mice
subgroup
challeng
sarscov
lung
sampl
collect
viral
load
detect
day
postchalleng
fig
specif
cell
vaccin
mice
detect
elispot
mous
kit
mabtech
sweden
accord
manufactur
protocol
brief
elispot
plate
coat
monoclon
antibodi
mab
overnight
c
block
steril
contain
fb
h
room
temperatur
singlecel
suspens
prepar
spleen
vaccin
mice
ad
well
concentr
cellswel
cell
incub
h
presenc
absenc
rbdpep
gml
plu
gml
bd
pharmingen
usa
c
co
follow
wash
pb
cell
sequenti
incub
biotinyl
antimous
mab
h
room
temperatur
streptavidinconjug
horseradish
peroxidas
hrp
h
room
temperatur
tmb
substrat
solut
around
min
extens
wash
incub
spot
cell
count
figur
immun
detect
procedur
mice
four
group
prime
rbdraav
rbdpeptid
plu
cpg
odn
rbdpep
blank
aav
boost
rbdraav
rbdpep
avv
respect
ten
day
postboost
sera
spleen
collect
mice
subgroup
detect
igg
na
titer
elisa
neutral
assay
respect
detect
th
ctl
respons
elispot
flow
cytometri
analysi
mice
subgroup
challeng
sarscov
viral
load
lung
tissu
determin
day
later
elispot
reader
system
immunospot
softwar
cellular
technolog
ltd
ohio
usa
specif
cell
vaccin
mice
measur
intracellular
cytokin
stain
flow
cytometri
analysi
singlecel
suspens
spleen
vaccin
mice
stimul
without
rbdpep
gml
plu
antibodi
gml
phorbol
myrist
acet
pma
ngml
sigma
usa
ionomycin
ngml
sigma
use
posit
control
cell
stimulatori
agent
incub
h
c
co
presenc
golgiplug
tm
contain
brefeldin
lml
bd
pharmingen
cell
fix
use
cytofixcytoperm
tm
plu
kit
accord
manufactur
protocol
bd
pharmingen
stain
directli
conjug
mab
specif
cell
surfac
antigen
percp
apc
intracellular
cytokin
pe
fitc
bd
pharmingen
min
c
appropri
isotypematch
control
cytokin
includ
stain
data
acquir
use
flow
cytomet
facscalib
bd
usa
lymphocyt
popul
gate
forward
light
scatter
versu
side
light
scatter
event
lymphocyt
subpopul
acquir
determin
percentag
cell
posit
specif
cytokin
data
analyz
cellquest
softwar
bd
bioscienc
usa
specif
igg
antibodi
sarscov
sera
vaccin
mice
test
elisa
use
protocol
describ
previous
modif
briefli
serial
dilut
mous
sera
ad
microtit
plate
precoat
protein
mixtur
sarscov
viral
lysat
plate
incub
c
min
follow
four
wash
pb
contain
tween
pbst
bound
antibodi
react
hrpconjug
goat
antimous
igg
dako
denmark
c
min
four
wash
tmb
substrat
solut
ad
plate
reaction
stop
ad
h
absorb
nm
measur
elisa
plate
reader
victor
multilabel
counter
perkinelm
usa
titer
na
sarscov
sera
vaccin
mice
measur
neutral
assay
vero
cell
previous
describ
briefli
cell
seed
well
cultur
plate
cultur
c
form
monolay
serial
twofold
dilut
serum
sampl
separ
mix
tcid
sarscov
strain
genbank
access
incub
c
h
ad
monolay
vero
cell
tetrapl
cell
infect
tcid
sarscov
without
viru
appli
posit
neg
control
respect
cytopath
effect
cpe
well
observ
daili
record
day
postinfect
neutral
titer
mous
antisera
complet
prevent
cpe
well
calcul
reedmuench
method
forti
day
postvaccin
mice
anaesthet
isofluran
inocul
l
sarscov
strain
tcid
accord
nation
anim
care
use
guidelin
approv
anim
laboratori
mice
sacrif
day
viru
challeng
mous
lung
remov
lung
tissu
store
c
virolog
test
viral
rna
copi
lung
tissu
challeng
mice
determin
quantit
reversetranscriptas
polymeras
chain
reaction
qrtpcr
accord
protocol
describ
previous
modif
briefli
total
rna
extract
mg
lung
tissu
use
rneasi
mini
kit
qiagen
inc
usa
cdna
synthes
use
random
primer
superscript
ii
rt
kit
invitrogen
usa
extract
rna
l
revers
transcrib
l
reaction
mixtur
contain
first
strand
buffer
mm
dtt
mm
dntp
ng
random
primer
u
rnaseout
u
ssiirt
c
min
follow
valu
present
mean
standard
error
se
statist
signific
among
differ
vaccin
group
calcul
student
test
use
stata
statist
softwar
p
valu
less
consid
signific
boost
vaccin
induc
similar
frequenc
cell
rbdraav
primerbdraav
boost
p
significantli
higher
group
p
fig
rbdraav
primerbdpep
boost
immun
elicit
higher
level
p
cell
respons
upregul
immun
respons
lower
level
p
cell
play
role
downregul
immun
respons
compar
rbdraav
primerbdraav
boost
vaccin
fig
howev
boost
dose
rbdpep
blank
aav
induc
signific
gener
cell
vaccin
mice
fig
c
result
suggest
rbdraav
primerbdpep
boost
vaccin
abl
induc
similar
stronger
respons
rbdraav
primerbdraav
boost
vaccin
examin
induct
ctl
respons
differ
vaccin
protocol
cell
spleen
vaccin
mice
stimul
without
rbdpep
cell
epitop
detect
cell
elispot
shown
fig
rbdraav
primerbdpep
boost
vaccin
induc
highest
level
cell
splenocyt
second
rbdraav
primerbdraav
boost
vaccin
splenocyt
rbdpep
rbdraav
primerbdraav
boost
vaccin
elicit
similar
level
cell
significantli
higher
vaccin
p
fig
ctl
respons
confirm
detect
lymphocyt
use
cell
surfac
marker
intracellular
cytokin
stain
follow
flow
cytometri
analysi
fig
result
demonstr
rbdraav
primerbdpep
boost
vaccin
induc
higher
level
cell
rbdraav
primerbdraav
boost
lymphocyt
induc
two
vaccin
similar
nevertheless
low
level
cell
detect
splenocyt
mice
rbdpep
primerbdpep
boost
aav
primeaav
boost
vaccin
result
demonstr
rbdraav
primerbdpep
boost
induc
stronger
ctl
respons
especi
lymphocyt
vaccin
detect
ctl
respons
flow
cytometri
analysi
specif
ctl
respons
vaccin
mice
detect
frequenc
cell
splenocyt
cell
surfac
marker
intracellular
cytokin
triplestain
use
flow
cytometri
analysi
cell
incub
rbdpeptid
plu
alon
use
neg
control
nc
least
lymphocyt
first
gate
frequenc
cell
analyz
indic
percentag
cell
graph
present
mean
valu
five
independ
experi
number
upper
right
corner
graph
repres
frequenc
cell
detect
antibodi
respons
vaccin
mice
vaccin
mice
detect
humor
immun
respons
day
first
vaccin
sarscovspecif
igg
titer
serum
sampl
detect
elisa
data
present
mean
se
five
mice
per
group
b
titer
serum
neutral
antibodi
measur
neutral
assay
titer
determin
highest
dilut
sera
could
complet
prevent
cpe
least
well
present
mean
se
five
mice
group
humor
immun
respons
vaccin
mice
evalu
detect
sarscovspecif
serum
igg
titer
use
elisa
shown
fig
rbdraav
primerbdpep
boost
abl
induc
high
level
sarscovspecif
igg
product
consist
rbdraav
primerbdraav
boost
vaccin
howev
rbdpep
primerbdpep
boost
induc
low
level
sarscovspecif
antibodi
rbdraav
primerbdpep
boost
could
also
induc
similar
level
neutral
antibodi
sarscov
rbdraav
primerbdraav
boost
vaccin
fig
contrast
titer
neutral
antibodi
induc
rbdpep
primerbdpep
boost
vaccin
significantli
lower
two
vaccin
strategi
p
similar
serum
igg
signific
neutral
antibodi
detect
mice
immun
aav
primeaav
boost
fig
b
result
indic
rbdraav
prime
rbdpep
boost
vaccin
could
induc
strong
neutral
antibodi
respons
detect
viral
replic
lung
tissu
sarscovchalleng
mice
vaccin
mice
subgroup
challeng
sarscov
viral
load
mous
lung
tissu
detect
qrtpcr
day
challeng
data
express
mean
se
viral
rna
copiesg
lung
tissu
four
mice
group
protect
efficaci
vaccin
differ
protocol
investig
mice
micegroup
intranas
challeng
sarscov
strain
day
postvaccin
mice
sacrif
day
challeng
viru
replic
lung
tissu
detect
qrtpcr
shown
fig
sarscov
viral
load
lung
tissu
significantli
reduc
mice
vaccin
rbdpep
low
level
viral
load
detect
lung
tissu
rbdraav
primerbdpep
boost
group
similar
lung
tissu
rbdraav
primerbdraav
boost
group
notabl
boost
dose
rbdpep
blank
aav
provid
protect
sarscov
challeng
significantli
higher
level
viral
load
p
fig
result
demonstr
like
boost
dose
rbdraav
vaccin
rbdraav
primerbdpep
boost
abl
significantli
inhibit
sarscov
infect
develop
vaccin
need
prevent
sar
case
diseas
reemerg
report
vaccin
sarscov
base
fulllength
protein
fragment
vaccin
mvabas
vaccin
contain
fulllength
protein
may
caus
enhanc
hepat
vaccin
anim
regard
fragment
sarscov
protein
practic
safer
develop
vaccin
shown
domain
especi
rbd
region
main
fragment
major
determin
elicit
na
sarscov
previou
studi
also
demonstr
candid
vaccin
base
rbd
induc
high
titer
neutral
antibodi
prevent
subsequ
sarscov
challeng
vaccin
mice
suggest
rbd
sar
protein
import
target
develop
safe
effect
sar
vaccin
primeboost
vaccin
use
strategi
develop
sar
vaccin
dna
vaccin
boost
inactiv
viru
viral
protein
fragment
shown
improv
immun
respons
includ
neutral
antibodi
respons
sarscov
also
report
immun
prime
dna
plasmid
encod
sarscov
n
protein
boost
adenovir
vector
express
protein
radn
effect
elicit
strong
sarscovnspecif
humor
cellular
immun
respons
vaccin
mice
studi
demonstr
immun
respons
could
enhanc
prime
rbdraav
boost
rbdpep
correspond
cell
epitop
rbd
region
sarscov
protein
compar
rbdraav
primeboost
vaccin
rbdraav
primerbdpep
boost
induc
similar
level
neutral
antibodi
respons
stronger
ctl
respons
fig
like
rbdraav
primeboost
vaccin
rbdraav
primerbdpep
boost
vaccin
could
also
induc
potent
protect
activ
mice
sarscov
challeng
fig
howev
signific
immun
respons
protect
effect
detect
mice
vaccin
rbdpep
blank
aav
alon
result
indic
rbdraav
primerbdpep
boost
vaccin
greatli
promot
cellular
immun
respons
neutral
antibodi
product
vaccin
mice
may
play
import
role
suppress
sarscov
infect
challeng
mice
recombin
aav
raav
base
vaccin
shown
promis
vaccin
candid
due
abil
induc
antigenspecif
humor
andor
cellular
immun
respons
pathogen
howev
im
vaccin
raav
especi
repeat
dose
might
induc
humor
immun
respons
viral
aav
capsid
protein
affect
immun
efficaci
raavbas
vaccin
respect
rbdraav
prime
specif
peptid
boost
may
prevent
disadvantag
induc
repeat
im
rbdraav
vaccin
elicit
similar
even
higher
immun
respons
protect
effect
one
key
issu
vaccin
develop
provid
crossprotect
infect
rapidli
mutat
virus
mutant
may
escap
protect
effect
vaccin
gener
cell
epitop
much
conserv
neutral
antibodi
epitop
compar
amino
acid
sequenc
peptid
use
boost
vaccin
human
sarscov
strain
civet
cat
sarscov
strain
deposit
genebank
complet
conserv
strain
one
strain
show
singl
amino
acid
chang
thu
strategi
boost
cell
peptid
may
plausibl
provid
crossprotect
quickli
mutat
virus
studi
rbdraav
primerbdpep
boost
rbdraav
primeboost
vaccin
provid
similar
protect
subsequ
sarscov
challeng
may
attribut
neutral
antibodi
respons
challeng
viru
induc
strategi
howev
former
may
probabl
induc
effect
protect
infect
virus
mutat
neutral
epitop
latter
former
elicit
significantli
stronger
specif
ctl
respons
latter
anoth
import
issu
vaccin
develop
whether
vaccin
provid
longterm
protect
previou
result
show
major
cell
cell
popul
present
work
also
demonstr
peptid
boost
vaccin
induc
much
higher
level
cell
found
antigenspecif
cell
preferenti
develop
longterm
effector
memori
cell
effector
memori
cell
predominantli
persist
peripher
site
key
portal
entri
pathogen
thu
vaccin
rbdraav
primrbdpep
boost
may
provid
longterm
protect
sarscov
conclus
prime
rbdraav
boost
cell
epitop
peptid
may
ideal
vaccin
strategi
provid
effect
crossand
longterm
protect
effect
infect
sarscov
includ
bear
mutat
neutral
epitop
